Background: With the increasing of novel therapeutics for the treatment of Biliary Tract Cancers (BTC), and the need to assess their socio-economic impacts for national licence approvals, it is as important as ever to have real-life data in national populations.

Methods And Results: We performed an audit of the first 2 year-activity (Sep 2019-Sep 2021) of the centralized West-of-Scotland-BTC clinic. 122 patients accessed the service, including 68% with cholangiocarcinoma (CCA), 27% with gallbladder cancer (GBC), and 5% with ampulla of Vater carcinoma with biliary phenotype (AVC). Median age at diagnosis was 66 (28-84), with 30% of newly diagnosed patients being younger than 60 years-old. Thirty-five cases (29%) underwent surgery, followed by adjuvant-chemotherapy in 66%. 60% had recurrent disease (80% with distant relapse). Sixty-four patients (58%) started first-line Systemic-AntiCancer-Treatment (SACT). Of these, 37% received second line SACT, the majority of which had iCCA and GBC. Thirty-% of those who progressed received third line SACT.

Conclusions: About 30% of BTC were eligible for curative surgery. Fifty-eight and twenty% of the overall cohort of advanced BTC patients received first and second line SACT. Our data suggest that reflex genomic profiling may not be cost-effective until molecularly driven strategies are limited to second line setting.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097428PMC
http://dx.doi.org/10.1186/s12885-024-12279-6DOI Listing

Publication Analysis

Top Keywords

real-life data
8
received second
8
second sact
8
insights clinical
4
clinical management
4
management real-life
4
data centralized
4
centralized west
4
west scotland
4
scotland biliary
4

Similar Publications

This study focuses on selecting a suitable 3D printer and defining experimental methods to gather the necessary data for determining the optimal filament material for printing components of the VEX GO and VEX IQ robotic kits. The aim is to obtain the required data to identify an appropriate filament material and set 3D printing parameters to achieve the desired mechanical properties of the parts while maintaining cost-effectiveness. Another key objective is achieving optimal operational functionality, ensuring the required part performance with minimal printing costs.

View Article and Find Full Text PDF

Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.

J Hepatol

January 2025

Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917). Electronic address:

Background And Aims: Bulevirtide (BLV) 2 mg/day is EMA approved for treatment of compensated chronic hepatitis due to Delta virus (HDV) infection, however real-life data in large cohorts of patients with cirrhosis are lacking.

Methods: Consecutive HDV-infected patients with cirrhosis starting BLV 2 mg/day since September 2019 were included in a European retrospective multicenter real-life study (SAVE-D). Patient characteristics before and during BLV treatment were collected.

View Article and Find Full Text PDF

Nurse Leader Perspectives on Precepting in a Graduate Nursing Administration Practicum.

J Nurs Adm

December 2024

Author Affiliations: Assistant Professor (Dr Hickman), Assistant Professor (Dr Petri), and Coordinator (Connors), University of Maryland School of Nursing, Baltimore.

Objective: To describe practicum experiences as perceived by nurse leader preceptors of graduate students in a nursing administration practicum.

Background: Practicum experiences in graduate nursing administration programs provide students with exposure to the real-life experiences of nurse leaders, bridging the gap between academic knowledge gained and the application of that information to the workplace. The literature lacks best practices for graduate nursing administration practicum experiences.

View Article and Find Full Text PDF

Temporary Transvenous Pacing Performed in the Intensive Care Unit or in the Catheterization Laboratory.

Pacing Clin Electrophysiol

January 2025

Service de rythmologie cardiaque, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France.

Background: Temporary transvenous pacing (TTP) is a common procedure, predominantly performed in the catheterization laboratory (cath lab) because of presumed lower complication rate. This study aims to evaluate the efficacy and safety of TTP placement in the ICU compared to TTP placement in the cath lab.

Methods: This retrospective, real-life study included all patients requiring TTP in a tertiary care ICU between 2019 and 2022.

View Article and Find Full Text PDF

Clinical control in COPD and therapeutic implications: The EPOCONSUL audit.

PLoS One

January 2025

Pulmonology Department, Department of Medicine, Hospital Clínico San Carlos, School of Medicine, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBER de Enfermedades Respiratorias (CIBERES), Universidad Complutense de Madrid, Madrid, Spain.

Objective: This study aimed to evaluate clinical control in chronic obstructive pulmonary disease (COPD), the consequences in terms of treatment decisions, and their potentially associated factors during follow-up of patients in real-life clinical practice.

Methods: EPOCONSUL 2021 is a cross-sectional audit that evaluated the outpatient care provided to patients with a diagnosis of COPD in respiratory clinics in Spain and multivariable logistic regression models to assess the relationships between clinical control and clinical inertia.

Results: 4225 patients from 45 hospitals in Spain were audited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!